Nabil specialises in IP and regulatory advice for clients ranging from start-ups to global players, with a particular focus on the life sciences and other technology-rich sectors.

Nabil provides pragmatic, commercially-minded advice with a focus on intellectual property strategy and regulatory compliance. In addition to advice on the identification, protection, commercialisation and enforcement of IP rights, Nabil supports clients with commercial contracts, due diligence, and regulatory compliance.

Prior to training as a solicitor, Nabil worked in early phase pharmaceutical R&D for AstraZeneca and chaired the Physical Organic Chemistry Group of the Royal Society of Chemistry.

显示完整简历 隐藏完整简历

最新新闻和观点

酒店与休闲

Advising IP Group on option exercise to accelerate development of first-in-class gene therapy for patients with cystic fibrosis

2021年10月29日

作者 Colin McCall 以及 Nabil Asaad, PhD

点击此处了解更多
技术、媒体与通信 (TMC)

Life sciences and healthcare in 2022 – legislators at work

2021年12月3日
Briefing

作者 Alison Dennis 以及 Justyna Ostrowska

点击此处了解更多
人工智能与机器学习

Artificial Intelligence Act (AIA) - Legal uncertainty for medical device manufacturers

2021年11月30日
Briefing

作者 Dr. Daniel Tietjen 以及 Dr. Niclas von Woedtke, MBA (Kellogg/ WHU)

点击此处了解更多
数字医疗

Digitisation in hospitals: Data protection as an obstacle or opportunity in Germany?

2021年11月24日
Briefing

作者 Mareike Christine Gehrmann 以及 Dr. Carolin Monsees

点击此处了解更多

与我会面: